دورية أكاديمية
أعرض في EDS

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression

التفاصيل البيبلوغرافية
العنوان: A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression
المؤلفون: Li, D., Pant, S., Ryan, D.P., Laheru, D., Bahary, N., Dragovich, T., Hosein, P.J., Rolfe, L., Saif, M.W., LaValle, J., Yu, K.H., Lowery, M.A., Allen, A., O'Reilly, E.M.
المصدر: In Pancreatology September-October 2014 14(5):398-402
قاعدة البيانات: ScienceDirect
الوصف
تدمد:14243903
DOI:10.1016/j.pan.2014.07.003